SNDX

AI Memo

Syndax

As of 2026-09-13/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Axatilimab Phase 2 topline readouts • 2026-12-31

Base target: $24 / p=50% prob

Biggest risk

The thesis remains exposed to variable new-patient starts, binary Phase 2 outcomes, pivotal-trial execution, and collaboration economics that limit Syndax's recognized share of Niktimvo sales. Post-print analyst revisions and forward-estimate changes are unavailable, so strong reported growth should not be extrapolated without further evidence.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Syndax has a dual-product commercial foundation: Q2 total revenue reached $73 million, Revuforj net revenue grew 91% year over year, and Niktimvo net revenue reached $60.3 million, producing $18.1 million of collaboration revenue. Longer Revuforj treatment duration, upcoming axatilimab readouts, and frontline AML development provide multiple upside paths [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-13

Base target

$24

p=50%

Bull target

$40

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Revuforj commercial uptake and treatment duration
Revuforj frontline AML expansion
Syndax has a dual-product commercial foundation: Q2 total revenue reached $73 million, Revuforj net revenue grew 91% year over year, and Niktimvo net revenue reached $60.3 million, producing $18.1 million of collaboration revenue.

BearKey bullets

Frontline AML expansion remains subject to enrollment, clinical efficacy, safety, regulatory, and timing risk.
Negative or ambiguous Q4 2026 axatilimab data in either IPF or frontline cGVHD could materially reduce pipeline value.
Niktimvo economics are shared through a collaboration: $60.3 million of Q2 net revenue resulted in $18.1 million of Syndax collaboration revenue [#SEC-8K-2026-08-04].

WatchKey bullets

Axatilimab Phase 2 topline readouts

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $24 (p=50%)

Target spread vs base: +67% / -62%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $24 (p=50%)Bear Target: $9 (p=25%)

Commentary

Available coverage is limited but favorable toward Q2 revenue growth and commercial execution. The evidence supports cautious optimism rather than a high-conviction rerating: market-reaction attribution and post-earnings analyst revisions are unavailable, while social, options, short-interest, and employee-sentiment inputs lack sufficient coverage and should not be interpreted as neutral or positive signals.

As of 2026-09-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Revuforj commercial uptake and treatment duration
Revuforj frontline AML expansion

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-09-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Axatilimab Phase 2 topline readouts
Syndax expects Q4 2026 topline data from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis and frontline chronic graft-versus-host disease. Favorable results could materially expand the program's opportunity, while disappointing data would impair pipeline optionality [#SEC-8K-2026-08-04].
Prob 40.00% • Move 22.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Revuforj commercial uptake and treatment duration
2026-11-15
Revuforj generated $54.7 million of Q2 2026 net revenue, up 91% year over year and 12% sequentially, while prescriptions increased 15% sequentially. Management attributed growth partly to longer treatment duration, but noted fluctuations in new-patient starts; the next commercial update should test whether duration-led growth persists [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-12].
Prob 65% • Move 15% • Priced-in 45%

Long-term Catalysts

Months to a year

Revuforj frontline AML expansion
2027-09-30
Management reported global site initiation and patient enrollment in pivotal frontline AML trials. Successful development could broaden Revuforj beyond its current settings, but timing and clinical outcomes remain uncertain [#SEC-8K-2026-08-04].
Prob 45% • Move 30% • Priced-in 20%

Risks

Frontline AML expansion remains subject to enrollment, clinical efficacy, safety, regulatory, and timing risk.
Negative or ambiguous Q4 2026 axatilimab data in either IPF or frontline cGVHD could materially reduce pipeline value.
Niktimvo economics are shared through a collaboration: $60.3 million of Q2 net revenue resulted in $18.1 million of Syndax collaboration revenue [#SEC-8K-2026-08-04].
Recent CEO and R&D-chief Form 4 activity included option exercises followed by open-market sales; this is not operating evidence but warrants monitoring [#SEC-FORM4-2026-07-09] [#SEC-FORM4-2026-06-12].
Revuforj growth could decelerate if longer treatment duration fails to offset fluctuations in new-patient starts.
The supplied peer set is loose, and no verified post-earnings analyst revisions, options data, short-interest data, or social-sentiment coverage are available.

Peers

Symbol	Summary
ANAB	AnaptysBio is a similar-market-cap biotechnology reference from the supplied peer set, but indication, mechanism, commercial-stage, and pipeline comparability are unconfirmed; valuation weight should therefore be limited.
ANIP	ANI Pharmaceuticals is a similar-market-cap sector comparator useful for broad commercial-execution context, but it is not established here as a direct oncology or mechanism peer.
ETON	Eton Pharmaceuticals provides another same-sector, similar-cap comparison, although the packet does not establish direct product, indication, or development-stage overlap with Syndax.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-13

Loading AI feed…

Symbol

Summary

ANAB

AnaptysBio is a similar-market-cap biotechnology reference from the supplied peer set, but indication, mechanism, commercial-stage, and pipeline comparability are unconfirmed; valuation weight should therefore be limited.

ANIP

ANI Pharmaceuticals is a similar-market-cap sector comparator useful for broad commercial-execution context, but it is not established here as a direct oncology or mechanism peer.

ETON

Eton Pharmaceuticals provides another same-sector, similar-cap comparison, although the packet does not establish direct product, indication, or development-stage overlap with Syndax.